<DOC>
	<DOCNO>NCT02070575</DOCNO>
	<brief_summary>The purpose study investigate new blood test look PSA group PSA relate protein patient 's blood indicate men surgery rise PSA could benefit treatment , and/or indicate men high risk recurrence initial treatment give .</brief_summary>
	<brief_title>Evaluation Molecular Forms PSA Human Kallikrein 2 Cohort Patients With Locally Resected Prostate Cancer But Biochemical Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<criteria>All patient treat radical prostatectomy develop rise serum PSA ≥ 0.05ng/ml receive kind additional therapy . Patients additional therapy post radical prostatectomy eligible study ≥1 year pass since treatment patient develop rise serum PSA ≥0.05ng/ml . Previous additional therapy prostate cancer , less 1 year ago No evidence rise PSA Patients unwilling undergo venesection</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PSA</keyword>
	<keyword>Human Kallikrein 2</keyword>
	<keyword>locally resect prostate cancer</keyword>
	<keyword>biochemical recurrence</keyword>
	<keyword>14-041</keyword>
</DOC>